CoChat

Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential

Open access
Gregory, Karen J., Dong, Elizabeth N., Meiler, Jens, Conn, P. Jeffrey · 2011 · Neuropharmacology
Cited by 119

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Allosteric modulation of G protein-coupled receptors (GPCRs) represents a novel approach to the development of probes and therapeutics that is expected to enable subtype-specific regulation of central nervous system target receptors. The metabotropic glutamate receptors (mGlus) are class C GPCRs that play important neuromodulatory roles throughout the brain, as such they are attractive targets for therapeutic intervention for a number of psychiatric and neurological disorders including anxiety, depression, Fragile X Syndrome, Parkinson’s disease and schizophrenia. Over the last fifteen years, selective allosteric modulators have been identified for many members of the mGlu family. The vast majority of these allosteric modulators are thought to bind within the transmembrane-spanning domains of the receptors to enhance or inhibit functional responses. A combination of mutagenesis-based studies and pharmacological approaches are beginning to provide a better understanding of mGlu allosteric sites. Collectively, when mapped onto a homology model of the different mGlu subtypes based on the β2-adrenergic receptor, the previous mutagenesis studies suggest commonalities in the location of allosteric sites across different members of the mGlu family. In addition, there is evidence for multiple allosteric binding pockets within the transmembrane region that can interact to modulate one another. In the absence of a class C GPCR crystal structure, this approach has shown promise with respect to the interpretation of mutagenesis data and understanding structure-activity relationships of allosteric modulator pharmacophores.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2010.07.007

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor

    Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637 · cited 2×

    “To identify the sites at which allosteric modulators bind mGlus, initial mutational sites were chosen based on models predicting a pocket that may resemble the site where 11-cis-retinal, an inverse agonist, binds in bovine rhodopsin (Palczewski et al., 2000; Teller et al., 2001).”
    BackgroundInfluential
  • Can the pharmaceutical industry reduce attrition rates?

    Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×

    “Thus, allosteric modulation represents an exciting novel means of targeting GPCRs particularly for CNS disorders, a therapeutic area with one of the highest rates of attrition in drug discovery (Kola and Landis, 2004).”
    Background
  • Altered synaptic plasticity in a mouse model of fragile X mental retardation

    Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×

    “Indeed, psychostimulant adverse effects were reported in early fenobam clinical trials (Itil et al., 1978; Friedmann et al., 1980; Pecknold et al., 1982), although whether or not this was due to interactions with mGlu 5 , an unknown interaction or through the formation of active metabolites remains…”
    Background
  • Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

    Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063 · cited 3×

    “In brain regions implicated in the pathology of schizophrenia it is hypothesized that hypofunction of NMDA receptors leads to decreased downstream activation of GABAergic neurons resulting in disinhibition and an overall increase in excitation (Swanson et al., 2005; Conn et al., 2009a).”
    Background
  • Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

    Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 1×

    “In a recent clinical trial, LY2140023, an oral prodrug of the orthosteric agonist LY404039, improved the positive and negative symptoms of schizophrenic patients with a similar efficacy to olanzapine, without the side effects associated with typical and atypical antipsychotics (Patil et al., 2007).”
    Background
  • Correction of Fragile X Syndrome in Mice

    Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979 · cited 1×

    “Administration of MPEP to FXS mice reduces anxiety and seizures (Yan et al., 2005), whilst crossbreeding of FXS mice with mGlu 5 knock-out mice suggest that a number of fragile X phenotypes can be corrected by reducing levels of mGlu 5 (Dolen et al., 2007).”
    Background
  • 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

    Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725 · cited 1×

    “…5 activity in electrophysiological preparations (O'Brien et al., 2003, 2004; Chen et al., 2007; Ayala et al., 2009) as well as in rodent behavioral models (Kinney et al., 2005; Balschun et al., 2006; Lecourtier et al., 2007; Gass and Olive, 2009; Uslaner et al., 2009; Stefani and Moghaddam, 2010).”
    Background
  • A new benzodiazepine pharmacology

    Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×

    “For example benzodiazepines, positive allosteric modulators (PAMs) of GABAA receptors, are an effective and safe treatment for anxiety and sleep disorders (Mohler et al., 2002).”
    Background
  • FMR1 and the fragile X syndrome: Human genome epidemiology review

    Crawford, D. C., Acuña, J. M., & Sherman, S. L. (2001) · Genetics in Medicine · doi:10.1097/00125817-200109000-00006 · Cited by 711 · cited 1×

    “Fragile X Syndrome (FXS) is the leading cause of autism and the most common form of inherited mental retardation (Crawford et al., 2001; Garber et al., 2008).”
    Background
  • Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors

    Pin, J.-P., Galvez, T., & Prézeau, L. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00038-x · Cited by 662 · cited 2×

    “Most class C GPCRs are distinguished by their large extracellular N-terminal domain, termed the Venus Flytrap domain (VFD), that contains the endogenous ligand-binding site (Pin et al., 2003).”
    Background

Show all 20 references

Cited by

See all 119

Metadata

Authors
Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2011-01
Volume
60
Issue
1
Pages
66-81
ISSN
0028-3908 (ISSN-L)
OpenAlex
W1994864252
Cited by
119
References
20
FWCI
4.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential. https://app.cochat.ai/papers/10.1016/j.neuropharm.2010.07.007
The paper
Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2011). Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2010.07.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.